FDA brings GSK’s Blenrep back to the market in multiple myeloma

The FDA has approved GSK’s Blenrep as a second-line multiple myeloma drug, overriding a negative advisory committee vote and clearing the way for a relaunch in the US.

The approval comes after a three-month …

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registeration number 16808844